Home

Indoco Remedies Ltd EPS

Image

Indoco Remedies Ltd

NSE: INDOCO

EPS

₹ -12.02

Last updated on: Jan 13, 2026

Key Highlights

  • The Earning per Share of Indoco Remedies Ltd is ₹ -12.02 as of 13 Jan 26 .
  • The earning per share of Indoco Remedies Ltd changed from ₹ 0.2 to ₹ -1 over 6 quarters. This represents a CAGR of NaN% .

Historical Earning per Share of Indoco Remedies Ltd

No data available

* All values are in

Company Fundamentals for Indoco Remedies Ltd

Market Cap

1,984 Cr

EPS

0.0

P/E Ratio (TTM)

0.0

P/B Ratio (TTM)

2.0

Day’s High

219.75

Day’s Low

209.05

DTE

1.0

ROE

-11.3

52 Week High

348.1

52 Week Low

190.0

ROCE

-2.1

Market Price of Indoco Remedies Ltd

1M

1Y

3Y

5Y

Monitoring Indoco Remedies Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
13 Jan 2026215.15
12 Jan 2026215
09 Jan 2026218.75
08 Jan 2026221.4
07 Jan 2026224.75
06 Jan 2026229.85
05 Jan 2026227.95
02 Jan 2026228.35
01 Jan 2026237.05
31 Dec 2025234.8

SWOT Analysis Of Indoco Remedies Ltd

Strength

3

che

Weakness

2

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Indoco Remedies Ltd

Asset Value vs Market Value of Indoco Remedies Ltd

Market Value

1,985

Asset Value

Value addition

0.9 X

1,030

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Indoco Remedies Ltd1984
Sun Pharmaceutical Industries Ltd415037
Divis Laboratories Ltd170795
Torrent Pharmaceuticals Ltd133332
Cipla Ltd116933
Lupin Ltd99436

Historical Market Cap of Indoco Remedies Ltd

No data available

* All values are in crore

Historical Revenue of Indoco Remedies Ltd

No data available

* All values are in crore

Historical EBITDA of Indoco Remedies Ltd

No data available

* All values are in crore

Historical Net Profit of Indoco Remedies Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Indoco Remedies Ltd News Hub

Indoco Remedies receives USFDA approval for Lofexidine Tablets 0.18 mg

Indoco Remedies announced the receipt of final approval from the USFDA for Abbreviated New Drug Appl

Read more

21 Aug 24

Indoco Remedies spurts on receiving USFDA nod for Lofexidine tablets

The generic equivalent of Lucemyra Tablets will market to USWM, LLC. 'Indoco has been granted a Comp

Read more

21 Aug 24

Indoco Remedies fixes record date for final dividend

Indoco Remedies has fixed 19 September 2024 as record date for determining entitlement of members to

Read more

30 Aug 24

Indoco Remedies AGM scheduled

Indoco Remedies announced that the Annual General Meeting (AGM) of the company will be held on 26 Se

Read more

31 Aug 24

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Indoco Remedies Ltd

What is the EPS of Indoco Remedies Ltd stock?

The Earnings Per Share (EPS) of Indoco Remedies Ltd is 0.0. An EPS is the amount of net income attributed to each share of a common stock.

How is Indoco Remedies Ltd EPS calculated?

The EPS of Indoco Remedies Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Indoco Remedies Ltd report its EPS?

Indoco Remedies Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Indoco Remedies Ltd EPS?

Factors that influence the EPS of Indoco Remedies Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Indoco Remedies Ltd EPS growth indicate future performance?

Yes, consistent growth in Indoco Remedies Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions